PBE - Invesco Dynamic Biotechnology & Genome ETF
| Assets | $299.93M |
| NAV | $75.55 |
| Expense Ratio | 0.58% |
| PE Ratio | 51.90 |
| Beta (5Y) | 1.08 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Mar 23, 2020 |
| 1-Year Return | - |
| Trading Day | April 16 |
| Last Price | $75.24 |
| Previous Close | $75.54 |
| Change ($) | -0.30 |
| Change (%) | -0.39% |
| Day's Open | 76.67 |
| Day's Range | 74.24 - 76.67 |
| Day's Volume | 5,367 |
| 52-Week Range | 51.07 - 84.86 |
Fund Description
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
| Asset Class Equity | Sector Biotech |
| Region North America | Inception Date Jun 23, 2005 |
| Exchange NYSEARCA | Ticker Symbol PBE |
| Index Tracked Dynamic Biotechnology & Genome Intellidex Index | |
Top 10 Holdings
48.41% of assets| Name | Symbol | Weight |
|---|---|---|
| Bio-Techne | TECH | 5.62% |
| Amgen | AMGN | 5.55% |
| Qiagen | QGEN | 5.18% |
| Alexion Pharmaceuticals | ALXN | 5.07% |
| Seagen | SGEN | 4.93% |
| Catalent | CTLT | 4.89% |
| BioMarin Pharmaceutical | BMRN | 4.76% |
| Illumina | ILMN | 4.46% |
| Five Prime Therapeutics | FPRX | 4.44% |
| Intellia Therapeutics | NTLA | 3.51% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 23, 2020 | $0.029 | Mar 31, 2020 |
| Sep 24, 2018 | $0.002 | Sep 28, 2018 |
| Jun 16, 2017 | $0.215 | Jun 30, 2017 |
| Mar 17, 2017 | $0.056 | Mar 31, 2017 |
| Dec 16, 2016 | $0.121 | Dec 30, 2016 |
| Sep 16, 2016 | $0.028 | Sep 30, 2016 |
Many would like to follow Ark Investment Management founder Cathie Wood's vision due to her success. She says that digital wallets and genomics will be the next two biggest disruptive trends after Tesla...
The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “...
Sector ETF report for PBE
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.
Sector ETF report for PBE
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
Sector ETF report for PBE
In a sea of red stocks on Wednesday, as fear grips markets due to another spike in coronavirus cases throughout the country, Gilead Sciences is one of the few bright spots in the stock market.
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.
Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.
These biotech ETFs could be standouts again in 2020, particularly if genomics stocks rally
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
Many biotech ETFs and other funds have fallen sharply off their highs in recent months.
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.
Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.
Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.
The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.
Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.
Sector ETF report for PBE